RNPC3 and neoplasm: To test this hypothesis, we knocked out ENG in the SUM102-MerTKC2 clone via ribonucleoprotein (RNP)-mediated CRISPR technology (Figure 6A) and examined the cell migration and tumor growth of the resulting knockout clones (SUM102-MerTKC2-crENG).